Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Henry Eriksson

Showing results (21-30 of 40) with videos related to

Pageof 4
Sort By:
Plos One|February 5, 2019
Age and sex related self-reported symptoms in a general population across 30 years: Patterns of reporting and secular trendAnnika Bardel, Mari-Ann Wallander, Thorne Wallman, et al.
Thrombosis Research|November 15, 2002
Pharmacokinetics, pharmacodynamics and clinical effects of the oral direct thrombin inhibitor ximelagatran in acute treatment of patients with pulmonary embolism and deep vein thrombosisKarin Wåhlander, Leif Lapidus, Carl-Gustav Olsson, et al.
Thrombosis and Haemostasis|July 15, 2016
Treatment of acute pulmonary embolism with dabigatran versus warfarin. A pooled analysis of data from RE-COVER and RE-COVER IISamuel Z Goldhaber, Sebastian Schellong, Ajay Kakkar, et al.
British Journal of Haematology|March 4, 2006
Risk of recurrent venous thromboembolism or bleeding in relation to thrombophilic risk factors in patients receiving ximelagatran or placebo for long-term secondary prevention of venous thromboembolismKarin Wåhlander, Henry Eriksson, Torbjörn Lundström, et al.
Journal of Thrombosis and Haemostasis : JTH|July 13, 2021
Post-thrombotic syndrome in patients with venous thromboembolism treated with dabigatran or warfarin: A long-term cross-sectional follow-up of RE-COVER study patientsHilde Skuterud Wik, Susan R Kahn, Henry Eriksson, et al.
BMJ Open|November 3, 2012
A population-based study of nearly 15 000 observations among Swedish women and men during 1973-2003Christina Halford, Catharina Welin, Johan Bogefeldt, et al.
Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology|April 6, 2015
The risk of atrial fibrillation in the general male population: a lifetime follow-up of 50-year-old menZacharias Mandalenakis, Lotta Von Koch, Henry Eriksson, et al.
Thrombosis and Haemostasis|December 5, 2017
Dabigatran versus Warfarin for Acute Venous Thromboembolism in Elderly or Impaired Renal Function Patients: Pooled Analysis of RE-COVER and RE-COVER IISamuel Z Goldhaber, Sam Schulman, Henry Eriksson, et al.
Vascular Medicine (London, England)|November 4, 2016
Efficacy of dabigatran versus warfarin in patients with acute venous thromboembolism in the presence of thrombophilia: Findings from RE-COVER®, RE-COVER™ II, and RE-MEDY™Samuel Z Goldhaber, Henry Eriksson, Ajay Kakkar, et al.
Lakartidningen|May 15, 2010
[Diagnosis of pulmonary embolism in pregnant women. Scintigraphy or computer tomography?]Ulf Nyman, Marika Bajc, Henry Eriksson, et al.
Pageof 4

Showing results (21-30 of 40) with videos related to

Sort By:
Pageof 4
Plos One|February 5, 2019
Age and sex related self-reported symptoms in a general population across 30 years: Patterns of reporting and secular trendAnnika Bardel, Mari-Ann Wallander, Thorne Wallman, et al.
Thrombosis Research|November 15, 2002
Pharmacokinetics, pharmacodynamics and clinical effects of the oral direct thrombin inhibitor ximelagatran in acute treatment of patients with pulmonary embolism and deep vein thrombosisKarin Wåhlander, Leif Lapidus, Carl-Gustav Olsson, et al.
Thrombosis and Haemostasis|July 15, 2016
Treatment of acute pulmonary embolism with dabigatran versus warfarin. A pooled analysis of data from RE-COVER and RE-COVER IISamuel Z Goldhaber, Sebastian Schellong, Ajay Kakkar, et al.
British Journal of Haematology|March 4, 2006
Risk of recurrent venous thromboembolism or bleeding in relation to thrombophilic risk factors in patients receiving ximelagatran or placebo for long-term secondary prevention of venous thromboembolismKarin Wåhlander, Henry Eriksson, Torbjörn Lundström, et al.
Journal of Thrombosis and Haemostasis : JTH|July 13, 2021
Post-thrombotic syndrome in patients with venous thromboembolism treated with dabigatran or warfarin: A long-term cross-sectional follow-up of RE-COVER study patientsHilde Skuterud Wik, Susan R Kahn, Henry Eriksson, et al.
BMJ Open|November 3, 2012
A population-based study of nearly 15 000 observations among Swedish women and men during 1973-2003Christina Halford, Catharina Welin, Johan Bogefeldt, et al.
Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology|April 6, 2015
The risk of atrial fibrillation in the general male population: a lifetime follow-up of 50-year-old menZacharias Mandalenakis, Lotta Von Koch, Henry Eriksson, et al.
Thrombosis and Haemostasis|December 5, 2017
Dabigatran versus Warfarin for Acute Venous Thromboembolism in Elderly or Impaired Renal Function Patients: Pooled Analysis of RE-COVER and RE-COVER IISamuel Z Goldhaber, Sam Schulman, Henry Eriksson, et al.
Vascular Medicine (London, England)|November 4, 2016
Efficacy of dabigatran versus warfarin in patients with acute venous thromboembolism in the presence of thrombophilia: Findings from RE-COVER®, RE-COVER™ II, and RE-MEDY™Samuel Z Goldhaber, Henry Eriksson, Ajay Kakkar, et al.
Lakartidningen|May 15, 2010
[Diagnosis of pulmonary embolism in pregnant women. Scintigraphy or computer tomography?]Ulf Nyman, Marika Bajc, Henry Eriksson, et al.
Pageof 4